Celcuity (NASDAQ:CELC) Now Covered by Analysts at Guggenheim

Guggenheim began coverage on shares of Celcuity (NASDAQ:CELC) in a research report report published on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $169.00 price target on the stock.

Several other brokerages have also issued reports on CELC. HC Wainwright reissued a “buy” rating and issued a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. JPMorgan Chase & Co. started coverage on Celcuity in a research note on Thursday, September 17th. They set an “overweight” rating and a $157.00 target price for the company. Craig Hallum reissued a “buy” rating and set a $178.00 price objective on shares of Celcuity in a research report on Wednesday, July 15th. Zacks Research lowered shares of Celcuity from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 13th. Finally, Wall Street Zen cut shares of Celcuity from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $152.14.

Celcuity Trading Up 4.3%

Shares of CELC stock traded up $2.75 on Friday, reaching $66.79. The company had a trading volume of 1,081,623 shares, compared to its average volume of 1,806,096. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The stock has a market cap of $3.27 billion, a PE ratio of -14.18 and a beta of 0.16. The company has a 50-day moving average of $75.11 and a 200-day moving average of $99.38. Celcuity has a 12 month low of $53.54 and a 12 month high of $151.02.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.21) earnings per share for the quarter, topping the consensus estimate of ($1.51) by $0.30. On average, equities analysts forecast that Celcuity will post -4.98 earnings per share for the current year.

Hedge Funds Weigh In On Celcuity

Hedge funds have recently made changes to their positions in the business. Assenagon Asset Management S.A. raised its holdings in shares of Celcuity by 685.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company’s stock valued at $117,579,000 after purchasing an additional 1,290,466 shares during the last quarter. Bank of America Corp DE acquired a new position in Celcuity during the second quarter worth $153,928,000. Wellington Management Group LLP boosted its holdings in Celcuity by 111.4% during the second quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock worth $94,848,000 after purchasing an additional 477,643 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in Celcuity by 10,659.7% during the third quarter. Pictet Asset Management Holding SA now owns 291,049 shares of the company’s stock worth $23,144,000 after purchasing an additional 288,344 shares during the last quarter. Finally, Jennison Associates LLC grew its position in Celcuity by 0.6% in the first quarter. Jennison Associates LLC now owns 231,140 shares of the company’s stock valued at $26,382,000 after purchasing an additional 1,436 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Key Stories Impacting Celcuity

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity reported a third-quarter loss of $1.21 per share, narrower than analysts’ expected loss of $1.51. The earnings beat may support sentiment. MarketBeat earnings report
• Positive Sentiment: The Q3 earnings-call summary highlighted strong launch momentum for Revtorpic, a potential positive commercial catalyst. Q3 2026 earnings-call highlights
• Positive Sentiment: Guggenheim kept its Buy rating and lowered its price target only modestly, from $171 to $169; the report cited substantial upside relative to the referenced share price. TickerReport article
• Negative Sentiment: Celcuity’s Q3 adjusted loss widened, a counterpoint to the per-share earnings beat and a reminder that the company remains loss-making. Celcuity Q3 adjusted loss widens

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.